Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Breaks Out of Its Small-Molecule Mind-Set

This article was originally published in Start Up

Executive Summary

Following similar moves by many of its Big Pharma peers, GSK is buying into large molecules, big time. In December 2006, it paid $454 million in cash for next-generation antibody specialist Domantis. Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for an antibody program from Genmab AS. For investors in privately held Domantis, whose most advanced drug candidate is preclinical, the acquisition was a much earlier than-anticipated exit.

You may also be interested in...



Rebuilding Big Pharma R&D: An Interview With GSK’s Ian Tomlinson

GlaxoSmithKline’s DPU model is industry’s most radical attempt to apply the lessons – and the pressures – of working in small biotech environments. BD and biopharma head Ian Tomlinson discusses what went wrong, and what GSK thinks it’s now doing right.

Best of the Blog: IN VIVO, December 2008

The best posts from the In Vivo Blog in December include: Is biotech running GSK? And the FDA's internal advisory meeting: what Avandia, Vioxx, Ketek, Elidel and Palladone have in common.

Best of the Blog: IN VIVO, December 2008

The best posts from the In Vivo Blog in December include: Is biotech running GSK? And the FDA's internal advisory meeting: what Avandia, Vioxx, Ketek, Elidel and Palladone have in common.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel